Jagsonpal Pharmaceuticals Ltd
JAGSNPHARMJagsonpal Pharmaceuticals Ltd
JAGSNPHARMPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
72.44 | 9.39 | 0.75% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Jagsonpal Pharmaceuticals Limited is engaged in pharmaceutical business. It specializes in developing and manufacturing bulk drugs and pharmaceutical formulations.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 144.15 | 157.14 | 126.99 | 168.26 | 161.10 | 192.34 | 221.01 | 242.44 | 217.98 | 234.96 | ||||||||||
Raw Materials | 65.35 | 67.34 | 65.19 | 53.43 | 54.94 | 75.50 | 83.35 | 88.04 | 76.08 | 197.56 | ||||||||||
Power & Fuel Cost | 2.26 | 2.12 | 1.00 | 1.41 | 0.64 | 0.52 | 0.47 | 0.29 | 0.17 | |||||||||||
Employee Cost | 37.84 | 40.95 | 41.88 | 46.61 | 50.37 | 53.98 | 57.68 | 65.18 | 61.80 | |||||||||||
Selling & Administrative Expenses | 26.58 | 30.19 | 27.56 | 32.23 | 38.34 | 31.88 | 42.50 | 41.66 | 41.09 | |||||||||||
Operating & Other expenses | -0.34 | -2.50 | 2.01 | 23.81 | 5.75 | 6.99 | 8.56 | 10.85 | 6.50 | |||||||||||
EBITDA | 12.46 | 19.04 | -10.65 | 10.77 | 11.06 | 23.47 | 28.45 | 36.42 | 32.34 | 37.40 | ||||||||||
Depreciation/Amortization | 3.09 | 1.99 | 0.32 | 1.02 | 1.13 | 1.09 | 1.53 | 1.21 | 1.66 | 4.22 | ||||||||||
PBIT | 9.37 | 17.05 | -10.97 | 9.75 | 9.93 | 22.38 | 26.92 | 35.21 | 30.68 | 33.18 | ||||||||||
Interest & Other Items | 5.30 | 2.64 | 0.66 | 0.75 | 0.51 | 0.51 | 0.29 | 0.41 | 0.81 | 0.90 | ||||||||||
PBT | 4.07 | 14.41 | -11.63 | 9.00 | 9.42 | 21.87 | 26.63 | 34.80 | 29.87 | 32.28 | ||||||||||
Taxes & Other Items | 0.83 | 2.53 | -0.08 | 1.78 | 1.54 | 4.82 | 7.78 | 8.09 | 7.41 | 7.98 | ||||||||||
Net Income | 3.24 | 11.88 | -11.55 | 7.22 | 7.88 | 17.05 | 18.85 | 26.71 | 22.46 | 24.30 | ||||||||||
EPS | 1.24 | 4.53 | -4.41 | 2.76 | 3.01 | 6.51 | 7.20 | 10.20 | 8.53 | 9.19 | ||||||||||
DPS | 0.10 | 0.10 | 0.10 | 0.25 | 0.50 | 1.00 | 4.00 | 5.00 | 5.00 | 5.00 | ||||||||||
Payout ratio | 0.08 | 0.02 | — | 0.09 | 0.17 | 0.15 | 0.56 | 0.49 | 0.59 | 0.54 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Jagsonpal Pharmaceuticals Ltd | 78.38 | 9.39 | 0.75% |
Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
Cipla Ltd | 28.51 | 4.38 | 0.89% |
Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare JAGSNPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.19%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Jagsonpal Pharmaceuticals Ltd
Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
WhiteOak Capital Pharma and Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0000% | Percentage of the fund’s portfolio invested in the stock 0.00% | Change in the portfolio weight of the stock over the last 3 months -0.70% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 50/65 (0) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
JAGSNPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.75%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.51 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 6, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateAug 21, 2023
Dividend/Share
₹5.00
Ex DateEx Date
Aug 21, 2023
Cash Dividend
Ex DateEx DateOct 29, 2021
Dividend/Share
₹4.00
Ex DateEx Date
Oct 29, 2021
Cash Dividend
Ex DateEx DateSep 22, 2021
Dividend/Share
₹1.00
Ex DateEx Date
Sep 22, 2021
Cash Dividend
Ex DateEx DateSep 22, 2020
Dividend/Share
₹0.50
Ex DateEx Date
Sep 22, 2020
Jagsonpal Pharmaceuticals has allotted 31,040 equity shares under ESOP. Consequently, the paid up equity share capital has increased to Rs. 13,27,29,810 (constituting of 2,65,45,962 equity shares of Rs. 5/- each). Powered by Capital Market - Live
Net profit of Jagsonpal Pharmaceuticals rose 53.41% to Rs 11.46 crore in the quarter ended September 2024 as against Rs 7.47 crore during the previous quarter ended September 2023. Sales rose 29.15% to Rs 74.69 crore in the quarter ended September 2024 as against Rs 57.83 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales74.6957.83 29 OPM %21.8114.47 - PBDT17.7110.42 70 PBT15.379.96 54 NP11.467.47 53 Powered by Capital Market - Live
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live
Net profit of Jagsonpal Pharmaceuticals declined 28.74% to Rs 5.33 crore in the quarter ended June 2024 as against Rs 7.48 crore during the previous quarter ended June 2023. Sales rose 2.14% to Rs 61.44 crore in the quarter ended June 2024 as against Rs 60.15 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales61.4460.15 2 OPM %16.6814.35 - PBDT11.4710.48 9 PBT10.4010.09 3 NP5.337.48 -29 Powered by Capital Market - Live
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 August 2024Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 5.31%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.08% to 0.06%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 25.48%, vs industry avg of 15.27%